[13 June 2013]
Products Affected - Description
Ketamine injection, Bedford
50 mg/mL, 10 mL vial, package of 10 (NDC 55390-0475-10)
Ketamine injection, Mylan Institutional
10 mg/mL, 20 mL vials (NDC 67457-0181-20)
Reason for the Shortage
- Bedford has ketamine on shortage due to manufacturing delays. Bedford anticipates full availability of each presentation the company reintroduces to market.
- Ben Venue voluntarily entered into a consent decree with FDA in late-January 2013 which allows Ben Venue to manufacture over 100 medications as long as they are compliant with the decree. Ben Venue supplies multiple products for Bedford Laboratories, a division of Ben Venue.
- JHP and Mylan Institutional could not provide a reason for the shortage.
Available Products
Ketamine injection, Hospira
50 mg/mL, 10 mL vial, package of 10 (NDC 00409-2053-10)
100 mg/mL, 5 mL vial, package of 10 (NDC 00409-2051-05)
Ketalar injection, JHP
10 mg/mL, 20 mL vials (NDC 42023-0113-10)
50 mg/mL, 10 mL vials (NDC 42023-0114-10)
100 mg/mL, 5 mL vials (NDC 42023-0115-10)
Ketamine injection, JHP
10 mg/mL, 20 mL vials (NDC 42023-0137-10)
50 mg/mL, 10 mL vials (NDC 42023-0138-10)
100 mg/mL, 5 mL vials (NDC 42023-0139-10)
Ketamine injection, Mylan Institutional
50 mg/mL, 10 mL vials (NDC 67457-0001-10)
100 mg/mL, 10 mL vials (NDC 67457-0108-10)
Estimated Resupply Dates
- Bedford has ketamine injection 50 mg/mL, 10 mL vials on long-term back order and it will not be manufactured until capacity permits.
- Mylan Institutional has ketamine injection 10 mg/mL, 20 mL vials on back order and the company estimates a release date in mid-June 2013.
Related Shortages
Updated
June 13, 2013; May 30, 2013; April 10, 2013; March 27, 2013; March 7, 2013; February 22, 2013; February 6, 2013; January 9, 2013; November 13, 2012; October 12, 2012; September 10, 2012; July 20, 2012; May 24, 2012; April 18, 2012; March 23, 2012; March 1, 2012; February 24, 2012; February 7, 2012; February 1, 2012; January 31, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins